WR-2721 reduces intestinal toxicity from concurrent gemcitabine and radiation treatment

Background. The nucleoside analog gemcitabine is a potent radiosensitizer o f both tumor and normal mucosa, so severe toxic reactions have resulted fro m its combination with radiation in some clinical treatment schedules for p ancreatic cancer. WR-2721 (amifostine) has been shown to reduce normal tiss ue toxicity produced from both radiation treatment and some chemotherapeuti cs. The aim of this study was to determine if WR-2721 can protect the gastr ointestinal mucosa from injury by concurrent gemcitabine and radiation trea tment. Methods and Materials. Gemcitabine was injected ip into C3Hf/Karn mice at a concentration of 33 mg/kg 24 h before whole-body irradiation. A single dos e (200 mg/kg) of WR-2721 was given 30 min before the radiation treatment or 30 min before gemcitabine or at both times. A quantitative assessment of t he chemotherapy/radiation-induced damage was carried out using the mouse mi crocolony assay for stem cell survival in the intestinal crypts. Results. W R-2721 given 30 min before gemcitabine followed 24 h later by radiation did not confer any protection to the jejunum (DMF 0.95). However, WR-2721 admi nistered 30 min before radiation without or with prior gemcitabine produced protection factors (PF) of 1.35 and 1.42 Conclusions. WR-2721 did not directly protect the gastrointestinal mucosa f rom gemcitabine toxicity, but it did protect the gemeitabine-radiosensitize d mucosa from acute radiation damage by a factor of 1.42. Therefore, in cli nical treatment protocols using concurrent chemoradiation with gemcitabine, WR-2721 may have clinical utility in protecting against radiation-induced mucosal toxicity.